Posted by Michael Wonder on 18 Jul 2022
Mycovia Pharmaceuticals announces U.S. availability of Vivjoa (oteseconazole) capsules, the first and only FDA approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection)
18 July 2022 - Vivjoa is now available in a network of partner pharmacies that includes mail order and local pickup options.
Mycovia’s patient support program, My Vivjoa, powered by vitaCare, is a comprehensive program designed to help patients with insurance coverage support, seamlessly applied savings and ongoing education.
